Literature DB >> 24464143

Fludarabine metabolite level on day zero does not affect outcomes of hematopoietic cell transplantation in patients with normal renal function.

C D Griffiths1, E S M Ng1, S B Kangarloo1, T S Williamson1, M A Chaudhry1, R Booker1, P Duggan1, P Yue1, L Savoie1, C Brown1, N Cox-Kennett1, J A Russell1, A Daly1, J Storek1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24464143     DOI： 10.1038/bmt.2013.234

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  5 in total

1.  Anti-thymocyte globulins capable of binding to T and B cells reduce graft-vs-host disease without increasing relapse.

Authors:  M Hoegh-Petersen; M A Amin; Y Liu; A Ugarte-Torres; T S Williamson; P J Podgorny; J A Russell; A Grigg; D Ritchie; J Storek
Journal:  Bone Marrow Transplant       Date:  2012-06-04       Impact factor: 5.483

Review 2.  Calcineurin inhibitor nephrotoxicity.

Authors:  Maarten Naesens; Dirk R J Kuypers; Minnie Sarwal
Journal:  Clin J Am Soc Nephrol       Date:  2009-02       Impact factor: 8.237

3.  F-ara-A pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and busulfan.

Authors:  M Bonin; S Pursche; T Bergeman; T Leopold; T Illmer; G Ehninger; E Schleyer; M Bornhauser
Journal:  Bone Marrow Transplant       Date:  2007-01-08       Impact factor: 5.483

4.  High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation.

Authors:  J R Long-Boyle; K G Green; C G Brunstein; Q Cao; J Rogosheske; D J Weisdorf; J S Miller; J E Wagner; P B McGlave; P A Jacobson
Journal:  Bone Marrow Transplant       Date:  2010-04-12       Impact factor: 5.483

5.  Fludarabine in the treatment of chronic lymphocytic leukemia: a review.

Authors:  Francesca Ricci; Alessandra Tedeschi; Enrica Morra; Marco Montillo
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423
  5 in total
  1 in total

1.  Personalized fludarabine dosing to reduce nonrelapse mortality in hematopoietic stem-cell transplant recipients receiving reduced intensity conditioning.

Authors:  Kinjal Sanghavi; Anthony Wiseman; Mark N Kirstein; Qing Cao; Richard Brundage; Kyle Jensen; John Rogosheske; Andy Kurtzweil; Janel Long-Boyle; John Wagner; Erica D Warlick; Claudio G Brunstein; Daniel J Weisdorf; Pamala A Jacobson
Journal:  Transl Res       Date:  2016-03-31       Impact factor: 7.012
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.